Aeglea BioTherapeutics Announces Grants of Inducement Awards
- None.
- None.
The stock options were granted with a 10-year term and an exercise price equal to
About Aeglea BioTherapeutics
In June 2023, Aeglea completed its asset acquisition of Spyre Therapeutics, Inc. and shifted its disease focus to IBD. Aeglea is advancing a pipeline of antibody therapeutics with the potential to transform the treatment of IBD. Aeglea's approach combines novel antibody engineering, rational therapeutic combinations, and precision immunology with the goal of maximizing efficacy, safety, and convenience of treatments for IBD. The company is developing antibodies targeting α4β7, TL1A, and IL-23.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-grants-of-inducement-awards-301976806.html
SOURCE Aeglea BioTherapeutics, Inc.
FAQ
What did Aeglea BioTherapeutics announce?
How many shares of common stock can be purchased with the stock options?
What is the exercise price of the stock options?
How will the stock options vest?